An interesting trial (REMAGUS02 Trial) conducted on breast cancer patients warned that celecoxib associated with neoadjuvant chemotherapy might worsen outcomes differentially by COX-2 expression [48]. The gene discussed is PTGS2; the disease is breast carcinoma.